不同止吐方案防治化疗所致恶心及呕吐效果观察

Effect of different Antiemetic Schemes on delayed nausea and vomiting caused by chemotherapy

目的探讨在肿瘤化疗治疗中采用不同止吐方案对化疗所致恶心及呕吐(CINV)的影响。方法选取2018年4-7月该院收治的晚期肺癌患者136例作为研究对象,根据采用的不同止吐治疗方案分为观察组(81例)和对照组(55例)。对照组静脉注射帕洛诺司琼0.25 mg、地塞米松5 mg联合抑酸剂,观察组口服阿瑞匹坦、静脉注射帕洛诺司琼0.25 mg、地塞米松5 mg联合抑酸剂。观察两组患者CINV发生情况及便秘发生情况结果观察组患者Ⅱ~Ⅲ度呕吐发生率明显低于对照组,差异有统计学意义(P<0.05);两组患者恶心发生率及便秘发生率比较,差异均无统计学意义(P>0.05);帕洛诺司琼不同使用时间患者CINV、便秘发生率比较,差异均无统计学意义(P>0.05)。结论针对晚期肺癌化疗患者采用阿瑞匹坦联合帕洛诺司琼止吐方案可较好地实现对呕吐发生程度的控制。但该用药方案对帕洛诺司琼增加用药时间并不会提高止吐效果,同时也不会增加发生便秘的风险,故具有较高的安全性。

Objective To investigate the effect of different antiemetic regimens on delayed nausea and vomiting(CINV)induced by chemotherapy drugs.Methods A total of 136 patients with advanced lung cancer who received treatment in our hospital from April 2018 to July 2018 were divided into two groups according to different antiemetic treatment plans,namely the control group(55 cases,intravenous palonosetron 0.25 mg+dexamethasone 5 mg+antacid)and the observation group(81 cases,oral arepidem+intravenous palonosetron 0.25 mg+dexamethasone 5 mg+antacid).The two groups were observed The occurrence of nausea,vomiting and constipation.Results The incidence of delayed vomitingⅡ-Ⅲin the observation group was 0.00%,and that in the control group was 9.1%,with statistical significance(P<0.05);there was no statistical significance in the incidence of nausea and constipation between the two groups(P>0.05);according to the comparison of the use days of palonosetron,the incidence of nausea,vomiting and constipation in each group was compared,with statistical significance(P<0.05)There was no statistical significance(P>0.05).Conclusion For patients with advanced lung cancer undergoing chemotherapy,the combination of aripitan and palonosetron can effectively control the incidence of delayed vomiting.However,increasing the duration of palonosetron does not improve the antiemetic effect,but it also does not increase the risk of constipation,so it has high safety.